Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
Zweifel, M Jayson, Gordon C Reed, N S Osborne, R Hassan, B Ledermann, J Shreeves, G Poupard, L Lu, S-P Balkissoon, J
Zweifel, M
Jayson, Gordon C
Reed, N S
Osborne, R
Hassan, B
Ledermann, J
Shreeves, G
Poupard, L
Lu, S-P
Balkissoon, J
Citations
Altmetric:
Abstract
A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.
Description
Date
2011-09
Publisher
Collections
Keywords
Type
Article
Citation
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. 2011, 22 (9):2036-41 Ann Oncol